Lincoln National Corp Sells 447 Shares of Edwards Lifesciences Co. (NYSE:EW)

Lincoln National Corp trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 1.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,494 shares of the medical research company’s stock after selling 447 shares during the period. Lincoln National Corp’s holdings in Edwards Lifesciences were worth $3,001,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in EW. BlackRock Inc. grew its stake in Edwards Lifesciences by 7.6% in the 4th quarter. BlackRock Inc. now owns 57,040,983 shares of the medical research company’s stock worth $7,389,659,000 after acquiring an additional 4,007,132 shares in the last quarter. State Street Corp grew its stake in Edwards Lifesciences by 3.7% in the 4th quarter. State Street Corp now owns 26,920,713 shares of the medical research company’s stock worth $3,487,578,000 after acquiring an additional 948,638 shares in the last quarter. Capital International Investors grew its stake in Edwards Lifesciences by 6.0% in the 4th quarter. Capital International Investors now owns 21,931,225 shares of the medical research company’s stock worth $2,841,315,000 after acquiring an additional 1,250,416 shares in the last quarter. Alliancebernstein L.P. grew its stake in Edwards Lifesciences by 4.6% in the 4th quarter. Alliancebernstein L.P. now owns 13,398,520 shares of the medical research company’s stock worth $1,735,778,000 after acquiring an additional 583,209 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Edwards Lifesciences by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 11,099,842 shares of the medical research company’s stock worth $1,434,219,000 after acquiring an additional 517,261 shares in the last quarter. 82.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on EW shares. Truist Financial dropped their target price on shares of Edwards Lifesciences from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Wednesday, July 20th. Cowen lowered their price target on shares of Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Citigroup lowered their price target on shares of Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating for the company in a research report on Tuesday, May 17th. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a research report on Tuesday, April 26th. Finally, Cowen lowered their price target on shares of Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Three equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $126.19.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Larry L. Wood sold 7,242 shares of the stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $96.13, for a total value of $696,173.46. Following the sale, the vice president now owns 206,069 shares in the company, valued at $19,809,412.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Larry L. Wood sold 7,242 shares of the stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $96.13, for a total value of $696,173.46. Following the sale, the vice president now owns 206,069 shares in the company, valued at $19,809,412.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Bernard J. Zovighian sold 4,811 shares of the stock in a transaction on Friday, August 5th. The stock was sold at an average price of $103.66, for a total transaction of $498,708.26. Following the completion of the sale, the vice president now owns 21,247 shares in the company, valued at approximately $2,202,464.02. The disclosure for this sale can be found here. In the last quarter, insiders have sold 120,854 shares of company stock worth $11,439,096. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Up 1.2 %

Shares of Edwards Lifesciences stock opened at $106.12 on Friday. The company has a current ratio of 3.37, a quick ratio of 2.60 and a debt-to-equity ratio of 0.10. Edwards Lifesciences Co. has a 12-month low of $85.58 and a 12-month high of $131.73. The firm has a market capitalization of $65.79 billion, a price-to-earnings ratio of 45.94, a PEG ratio of 3.09 and a beta of 1.12. The firm’s 50 day simple moving average is $97.35 and its two-hundred day simple moving average is $105.35.

Edwards Lifesciences (NYSE:EW – Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the company posted $0.64 EPS. The company’s revenue for the quarter was down .2% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Co. will post 2.51 EPS for the current year.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.